These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2185969)

  • 41. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of SMS 201-995 on basal and stimulated pancreatic secretion in rats.
    Guan D; Maouyo D; Sarfati P; Morisset J
    Endocrinology; 1990 Jul; 127(1):298-304. PubMed ID: 2361474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholecystokinin receptor antagonist loxiglumide: influence on bilio-pancreatic secretion and gastrointestinal hormones in man.
    Schmidt WE; Creutzfeldt W; Höcker M; Choudhury AR; Nustede R; Schleser A; Nitsche R; Rovati LC; Schafmayer A; Fölsch UR
    Digestion; 1990; 46 Suppl 2():232-9. PubMed ID: 2262057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of pancreatic secretion under long-term octreotide treatment in humans.
    Friess H; Bordihn K; Ebert M; Malfertheiner P; Kemmer T; Dennler HJ; Büchler MW
    Digestion; 1994; 55 Suppl 1():10-5. PubMed ID: 8132133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone disease: relationships with gallbladder contraction.
    Glasbrenner B; Domínguez-Muñoz JE; Nelson DK; Pieramico O; Holzwarth C; Riepl RL; Malfertheiner P
    Am J Gastroenterol; 1994 Mar; 89(3):404-10. PubMed ID: 8122654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Noradrenergic inhibition of canine gallbladder contraction and murine pancreatic secretion during stress by corticotropin-releasing factor.
    Lenz HJ; Messmer B; Zimmerman FG
    J Clin Invest; 1992 Feb; 89(2):437-43. PubMed ID: 1737835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effect of octreotide in acromegaly on insulin resistance.
    Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
    Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The BT-PABA/PAS test in tropical diabetes.
    Gagee P; Pemberton P; Lobley R; Chaloner C; Snehalatha C; Mohan V; Braganza JM
    Clin Chim Acta; 1992 Nov; 212(3):103-11. PubMed ID: 1477973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colonic transit influences deoxycholic acid kinetics.
    Veysey MJ; Thomas LA; Mallet AI; Jenkins PJ; Besser GM; Murphy GM; Dowling RH
    Gastroenterology; 2001 Oct; 121(4):812-22. PubMed ID: 11606495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of SMS 201-995 on exocrine pancreatic secretion in a patient with external pancreatic fistula.
    Ohta T; Nagakawa T; Mori K; Kanno M; Kayahara M; Ueno K; Miyazaki I
    Int J Pancreatol; 1992 Jun; 11(3):185-9. PubMed ID: 1517658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of octreotide, a long-acting somatostatin analogue, on plasma amino acid uptake by the pancreas.
    Gullo L; Pezzilli R; Ancona D; Labate AM; Barbara L
    Pancreas; 1991 Nov; 6(6):668-72. PubMed ID: 1780327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proceedings of the discussion, "Tolerability and safety of Sandostatin".
    Wass JA; Popovic V; Chayvialle JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):80-2. PubMed ID: 1518439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Wass JA
    Digestion; 1993; 54 Suppl 1():107-20. PubMed ID: 8103009
    [No Abstract]   [Full Text] [Related]  

  • 57. Sandostatin (octreotide acetate).
    Claussen D
    Gastroenterol Nurs; 1992 Dec; 15(3):122-4. PubMed ID: 1472557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The use of Sandostatin in the combined treatment of surgical diseases of the pancreas].
    Saenko VF; Lifshits IuZ; Kozhara SP; Usenko AIu; Andreeshchev SA; Kryzhevskiĭ VV; Olenin VV; Beliaeva OA
    Lik Sprava; 1997; (3):126-7. PubMed ID: 9377332
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Release of cholecystokinin and exocrine pancreatic secretion, gallbladder contraction--establishment of a radioimmunoassay specific for CCK33].
    Hosotani R; Inoue K; Takahashi J; Kogire M; Huang YS; Suzuki T; Tobe T
    Nihon Shokakibyo Gakkai Zasshi; 1986 Nov; 83(11):2383-92. PubMed ID: 3820762
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of small doses of somatostatin analog, octreotide, on gallbladder contractility in normal Chinese adults.
    Zhu XF; Shi YF; Qin-Dai ; Zhang JX; Harris AG
    Dig Dis Sci; 1992 Jan; 37(1):105-8. PubMed ID: 1345817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.